On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now


Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Inks First CBD Oil Commercial Sale; Looks to Grow in Key Spaces

  • Pure Extracts is preparing to deliver shipment of 85% pure CBD distillate
  • Company proud of quality offering produced in world-class facility
  • PULL uses proprietary state-of-the art, sub-critical/super-critical CO2extraction system

Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ), a plant-based extraction company, has signed a contract for its first CBD oil commercial sale on the wholesale market (https://ibn.fm/92kPG). Pure Extracts is preparing to deliver the first of what it anticipates will be multiple shipments this year of its 85% pure CBD distillate under this contract.

“We are excited to have completed our first commercial order, and we are proud of the quality of distillate that our extraction team has produced in our new, world-class facility,” said Pure Extracts CEO Ben Nikolaevsky.

According to a recent update, Pure Extracts finished construction of its state-of-the-art facility last year (https://ibn.fm/B65HW). Located about 20 minutes north of Whistler, British Columbia, the center is built to European Union GMP standards and is the perfect complement to Pure Extracts’ Standard Processing License, which the company received from Health Canada on September 25, 2020 through its wholly owned subsidiary, Pure Extracts Manufacturing Corp.

Pure Extracts is gaining a reputation for providing exceptionally pure THC and CBD full spectrum oil (“FSO”) and distillate. The company obtains such a high-quality offering by using its proprietary state-of-the art, sub-critical/super-critical CO2 extraction system. The distillate is ideally suited for use in most cannabis 2.0 products, including beverages, edibles and vape pens.

With such a high-quality product available, it is perhaps no surprise that the company is seeing success in the toll processing and white labeling space. Pure Extract offers the ideal solutions for LPs that lack the extraction expertise and requisite equipment to manufacture their own raw materials. In addition, Pure Extracts is also developing its own private label of products; the Pure Pulls and Pure Chews brand, which will include vape pens and edibles, will incorporate the company’s own full spectrum THC and CBD-based extracted oils.

In conjunction with the company’s commitment to strengthen its brand awareness and expand into new spaces, Pure Extracts is teaming up with Native Ads Inc. and Winning Media to create and execute digital advertising campaigns. Under the terms of the agreement, Native Ads and Winning Media will provide strategic digital media services, marketing coordination, content production and data analytics services — all designed to support Pure Extracts as it moves forward with its strategic growth and expansion plans.

Pure Extracts Technologies Inc., headquartered in Pemberton, British Columbia, is a plant-based extraction company with a new vertical in functional mushrooms with plans the enter burgeoning psychedelic mushroom sector once it receives a Dealer’s Licence from Health Canada. A Dealer’s Licence would allow the company to handle, manufacture and sell substances such as psilocybin and psilocin. The company is positioned to be the dominant extraction company and a leader in the rapid development and commercialization of functional and medicinal psychedelic products.

For more information, visit the company’s website at www.PureExtractsCorp.com.

NOTE TO INVESTORS: The latest news and updates relating to PULL are available in the company’s newsroom at https://ibn.fm/PULL

From Our Blog

Largely Untapped Market for Hallucinogenic Draws Attention of Researchers at XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT)

April 16, 2021

XPhyto Therapeutics Corp., a life sciences technology accelerator, is looking for ways to turn promising psychedelics into therapeutic pharmaceutical drugs, and recently added mescaline to its study profile Mescaline is illegal under U.S. federal law, but some state-centric efforts to legalize or decriminalize the hallucinogenic have launched in a manner similar to the populace effort […]

Rotate your device 90° to view site.